Gastrointestinal Physiological Changes and Their Relationship to Weight Loss Following the POSE Procedure
Overview
Authors
Affiliations
Background: Primary Obesity Surgery Endolumenal (POSE) is a novel bariatric endoscopic procedure that has been shown to reduce weight safely through 12 months. The study investigated potential mechanisms of weight loss following POSE.
Methods: Patients with class I-II obesity received transmural plications in the gastric fundus and distal gastric body. Patients were evaluated at baseline and at 2- and 6-month follow-up with gastric-emptying (GE) scintigraphy, a validated test of intake capacity (kcal) and plasma glucose homeostasis hormones/gastrointestinal peptides. Weight was recorded through 15 months. Mean data and 95% CIs are reported. Regression modeling assessed variables that influenced total weight loss (%TWL) and excess weight loss (%EWL).
Results: POSE was performed on 18 patients (14 F/4 M); mean age 39 years (34-44), body mass index (BMI, kg/m(2)) 36 (95% CI, 35; 37). At 15 months (n = 15), mean TWL was 19.1 ± 6.6% (15.5; 22.8) and EWL was 63.7 ± 25.1% (49.8; 77.6). At 2 and 6 months (n = 18), intake capacity decreased significantly from 901 (685; 1117) to 473 (345; 600) and 574 kcal (418; 730), respectively (p < 0.001). At 2 months, GE was delayed but returned to baseline levels at 6 months (n = 18). Glucose/insulin ratio improved (p < 0.05). Postprandial decrease in ghrelin was enhanced (p = 0.03) as well as postprandial increase in PYY (p = 0.001). The best model for EWL prediction 15 months after POSE (R (2): 66%, p = 0.006) included pre-POSE BMI, post-POSE GE, and postprandial PYY increase.
Conclusions: The POSE procedure was followed by significant sustained weight loss and improved glucose homeostasis and satiation peptide responses. Weight loss following POSE may be mediated through changes in gastrointestinal neuro-endocrine physiology.
Strategies to Manage Obesity: Endoscopic Bariatric and Metabolic Therapies.
Allencherril R, McCarty T Methodist Debakey Cardiovasc J. 2025; 21(2):74-83.
PMID: 39990755 PMC: 11844021. DOI: 10.14797/mdcvj.1518.
Jirapinyo P, Jaroenlapnopparat A, Thompson C Endosc Int Open. 2024; 12(12):E1458-E1464.
PMID: 39691741 PMC: 11651918. DOI: 10.1055/a-2463-9784.
The POSE-2 Procedure for People with Obesity: A Safe and Effective Treatment Option.
Jense M, Hodde T, Palm-Meinders I, Bours P, Soufidi K, Boerma E Obes Surg. 2024; 34(10):3686-3693.
PMID: 39235685 PMC: 11464541. DOI: 10.1007/s11695-024-07488-8.
Mechanism of action and selection of endoscopic bariatric therapies for treatment of obesity.
Ghusn W, Calderon G, Abu Dayyeh B, Acosta A Clin Endosc. 2024; 57(6):701-710.
PMID: 39206501 PMC: 11637673. DOI: 10.5946/ce.2024.005.
Combination Therapy of Endoscopic Gastric Remodeling with GLP-1RA for the Treatment of MASLD.
Jirapinyo P, Jaroenlapnopparat A, Zucker S, Thompson C Obes Surg. 2024; 34(5):1471-1478.
PMID: 38512644 DOI: 10.1007/s11695-024-07178-5.